AllianceBernstein’s UroGen Pharma URGN Stock Holding History

AllianceBernstein’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$786K	Buy	43,710 +8,670	+25%	+$235K	﹤0.01%	2504
2026 Q1	$821K	Hold	35,040	–	–	﹤0.01%	2423
2025 Q4	$821K	Hold	35,040	–	–	﹤0.01%	2433
2025 Q3	$699K	Hold	35,040	–	–	﹤0.01%	2510
2025 Q2	$480K	Sell	35,040 -35,377	-50%	-$339K	﹤0.01%	2661
2025 Q1	$779K	Sell	70,417 -128,842	-65%	-$1.37M	﹤0.01%	2359
2024 Q4	$2.12M	Buy	199,259 +175,859	+752%	+$2.11M	﹤0.01%	1928
2024 Q3	$297K	Sell	23,400 -10,830	-32%	-$161K	﹤0.01%	2924
2024 Q2	$574K	Buy	+34,230	New	+$487K	﹤0.01%	2599
2022 Q2	–	Sell	-24,500	Closed	-$213K	–	3383
2022 Q1	$213K	Hold	24,500	–	–	﹤0.01%	2978
2021 Q4	$233K	Hold	24,500	–	–	﹤0.01%	3018
2021 Q3	$412K	Hold	24,500	–	–	﹤0.01%	2834
2021 Q2	$374K	Buy	24,500 +2,600	+12%	+$47K	﹤0.01%	2933
2021 Q1	$427K	Hold	21,900	–	–	﹤0.01%	2732
2020 Q4	$395K	Hold	21,900	–	–	﹤0.01%	2705
2020 Q3	$422K	Hold	21,900	–	–	﹤0.01%	2612
2020 Q2	$572K	Hold	21,900	–	–	﹤0.01%	2518
2020 Q1	$391K	Hold	21,900	–	–	﹤0.01%	2478
2019 Q4	$731K	Hold	21,900	–	–	﹤0.01%	2406
2019 Q3	$522K	Hold	21,900	–	–	﹤0.01%	2526
2019 Q2	$787K	Buy	+21,900	New	+$807K	﹤0.01%	2415

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

AllianceBernstein's URGN Position: Q2 2026 in Review

AllianceBernstein increased its UroGen Pharma (URGN) stake by 25% in Q2 2026, buying an estimated $235K and bringing the position to 43,710 shares worth $786K. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

AllianceBernstein first reported a position in URGN in Q2 2019 and has held it in 21 quarters since. The position peaked at $2.12M in Q4 2024. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

AllianceBernstein held 43,710 shares of UroGen Pharma worth $786K as of Q2 2026.
AllianceBernstein bought 8,670 UroGen Pharma shares in Q2 2026, an estimated $235K.
UroGen Pharma made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2504 holding.
AllianceBernstein first reported a position in UroGen Pharma in Q2 2019 and has held it in 21 quarters since.
AllianceBernstein's UroGen Pharma position peaked at $2.12M in Q4 2024.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.